Preclinical Evaluation of INCA035784, a Novel T Cell–Redirecting Antibody for the Treatment of Calreticulin Mutation–Driven Myeloproliferative Neoplasms (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-553; Location: LEVEL 3, HALL B3; "Targeting the conserved mutCALR Ndomain with INCA035784 may have advantages over C-terminal–directed therapies, especially in patients harboring atypical mutCALR variants and those with canonical type 1/2 mutCALR. CD: cluster of differentiation."
Preclinical • Essential Thrombocythemia • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • CALR • CD34 • MPL
|
|
Liang-Chuan Wang 1; Eleanor Murphy 2; Veethika Pandey 1; Moritz Reichert 2; Ashwini Kulkarni 1; Yuqi Shen 2; Florian Laforets 2; Anna Godfrey 3; Sophie Michael 2; Obsie Baissa 2; Abdullah Khan 2; Mark Rupar 1; Chryssa Kanellopoulou 1; Ricardo Macarron 1; Patrick A Mayes 1; Bethan Psaila 2
|